MSK physicians Peter Bach and Leonard Saltz sparked a national debate in 2012 when they published an op-ed in the New York Times detailing Memorial Sloan Kettering’s refusal to include a new colorectal cancer drug on the hospital’s formulary because of its high cost. Drs. Bach and Saltz continue to engage the media in this discussion, appearing most recently on CBS's 60 Minutes. Both are available to discuss the burden these high prices have on patients, the current healthcare marketplace that allows cancer drugs to be priced so high, and what the medical community is poised to do about it. For more information and to set up an interview, email the Media Staff at email@example.com.
The first in a new class of immunotherapy drugs was granted FDA approval on September 4, 2014. MSK physicians played a major role in the clinical trials that led to its approval and are continuing to conduct trials using the therapy in melanoma and other cancers.
Physicians at Memorial Sloan Kettering have found that robotic surgery to remove a cancerous bladder did not reduce the risk of complications as compared with traditional open surgery. Findings were published this week in the New England Journal of Medicine. The study was conducted at MSK with surgeons experienced in both procedures and raises questions about the cost effectiveness of robotic surgery. For more information and to set up interviews with Dr. Bernard Bochner or Dr. Vincent Laudone, please contact Emily O’Donnell at firstname.lastname@example.org.
Memorial Sloan Kettering is proud and honored to announce it has been named the number one hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals. Since the inception of the revered list 25 years ago, MSK has held either the first or second spot each year.
Memorial Sloan Kettering experts are available to comment on research presented at the 2014 annual meeting of the American Society of Clinical Oncology, including research in immunotherapy and targeted therapy, as well as breast, prostate, colorectal, and lung cancers, among others. For more information and to set up interviews or access photos and video, email Caitlin Hool at email@example.com.
Memorial Sloan Kettering today launched an ambitious initiative to improve cancer care and research through genomic analysis. The new program will reshape clinical trials and speed the translation of novel molecular discoveries into routine clinical practice. The Marie-Josée and Henry R. Kravis Center for Molecular Oncology (CMO) is named in honor of Marie-Josée and Henry R. Kravis, whose transformative gift of $100 million will make it possible to realize the promise of precision oncology and support the development of new, individualized cancer therapies and diagnostic tools. For more information and to set up interviews or access photos and video, email the Media Staff at firstname.lastname@example.org.
Cancer will become the leading cause of death in the US by 2030 according to a new report, but rising healthcare costs and oncology workforce shortages threaten to limit access to high-quality cancer care.
Memorial Sloan Kettering’s achievements in blood and marrow stem cell transplantation are taking center stage at the 2014 BMT Tandem Meeting, a joint conference of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research, which runs from February 26 through March 2. At the meeting, Adult Bone Marrow Transplantation Service Chief Sergio Giralt will assume his role as ASBMT President for the coming year, while Richard O’Reilly, Chair of the Department of Pediatrics and Chief of the Pediatric Bone Marrow Transplant Service, will deliver one of the featured lectures. In addition, Memorial Sloan Kettering physician-scientists Robert Jenq and Yusuke Shono will be presenting two of the six “best abstracts” highlighted at the meeting, which were chosen from a total of 528 abstracts submitted from 30 countries. For more information and to set up interviews, email the Media Staff at email@example.com.
The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells.
A study published by the British Medical Journal questioning the benefit of yearly mammogram screenings has gained momentum in the media, while causing confusion among women and concern among experts in the field, including those at Memorial Sloan Kettering. Our experts agree that annual mammograms starting at age 40 save lives and decrease the likelihood that women will die of breast cancer by at least 25 to 30 percent. Medical oncologist Larry Norton and diagnostic radiologist Carol Lee are available to discuss. For more information and to set up an interview, email the Media Staff at firstname.lastname@example.org